scholarly journals Impact of Ospemifene on Quality of Life and Sexual Function in Young Survivors of Cervical Cancer: A Prospective Study

2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Nicoletta De Rosa ◽  
Giada Lavitola ◽  
Pierluigi Giampaolino ◽  
Ilaria Morra ◽  
Carmine Nappi ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cervical Cancer ◽  
Prospective Study ◽  
Sexual Function ◽  
Clinical Signs ◽  
Study Patient ◽  
Life Questionnaire ◽  
European Organization ◽  
Significant Difference

Background. Cervical cancer (CC) treatments impact quality of life (QoL) and sexual function (SF) of survivors. Treatment options to reduce sexual dysfunction are limited. The aim of this study was to assess the effectiveness of ospemifene in CC survivors with clinical signs and symptoms of vulvovaginal atrophy (VVA) focusing on their QoL and SF. Materials and Methods. Fifty-two patients with previous diagnosis of stage I-IIa CC suffering from VVA and treated with ospemifene were enrolled into a single arm prospective study. Patient underwent 6 months of therapy. At baseline and after 6 months all subjects performed Vaginal Health Index (VHI). The SF and QoL were measured by The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) and the Cervical Cancer Module (CXC-24). Results. After treatment a significant improvement of each parameter of VHI has been demonstrated. Global health status and emotional and social functioning scores improved significantly. On the contrary, general symptoms scales did not show significant difference from baseline data. Sexual activity, sexual vaginal functioning, body image, and sexual enjoyment scores increased significantly. Conclusion. Ospemifene seems to be effective in decreasing the VVA symptoms in CC survivors.

Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer.

1995 ◽  
Vol 13 (9) ◽  
pp. 2317-2323 ◽  
Author(s):  
M Hill ◽  
A Norman ◽  
D Cunningham ◽  
M Findlay ◽  
M Watson ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Colorectal Cancer ◽  
Advanced Colorectal Cancer ◽  
Symptomatic Improvement ◽  
Interferon Alfa ◽  
Life Questionnaire ◽  
European Organization ◽  
Significant Difference ◽  
Venous Infusion

PURPOSE The aim of this study was to investigate the effects of adding interferon alfa-2b (IFN) to protracted venous infusion fluorouracil (PVI 5-FU) from the start of treatment in patients with advanced colorectal cancer. PATIENTS AND METHODS Patients who attended our unit with histologically confirmed advanced colorectal cancer were randomized to receive either PVI 5-FU 300 mg/m2/d via Hickman line, and IFN 5 MU subcutaneously three times weekly, or PVI 5-FU alone. Treatment was given for a maximum of two 10-week blocks, with a 2-week gap for reassessment of all parameters. Quality of life (QL) was measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) pretreatment and every 6 weeks thereafter. RESULTS A total of 160 patients were randomized, with 155 eligible for assessment. Radiologic response was observed in 43 patients (28%): 17 of 77 (22%) in the 5-FU-plus-IFN arm (all partial responses [PRs]) and 26 of 78 (33%) in the 5-FU-alone group (complete responses [CRs] and 22 PRs) (difference not significant). Symptomatic improvement occurred in the majority of patients, and equally in both arms: 61% to 80% depending on the symptom. There was no significant difference between the two groups in failure-free survival (median, 161 v 193 days) or overall survival (median, 328 v 357 days). However, patients who received IFN did experience significantly more toxicity in the form of leukopenia (P = .001), neutropenia (P = .04), mucositis (P = .008), and alopecia (P = .0002). There were no toxic deaths and few notable differences in QL between the two arms. CONCLUSION This study confirms that PVI 5-FU is effective in treating the symptoms associated with metastatic colorectal carcinoma, with only mild to moderate toxicity and maintenance of QL. IFN 5 MU three times weekly does not enhance these palliative benefits.

Hypofractionated Palliative Radiotherapy (17 Gy per two fractions) in Advanced Non–Small-Cell Lung Carcinoma Is Comparable to Standard Fractionation for Symptom Control and Survival: A National Phase III Trial

2004 ◽  
Vol 22 (5) ◽  
pp. 801-810 ◽  
Author(s):  
Stein Sundstrøm ◽  
Roy Bremnes ◽  
Ulf Aasebø ◽  
Steinar Aamdal ◽  
Reidulv Hatlevoll ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Symptom Relief ◽  
Small Cell ◽  
Phase Iii ◽  
Life Questionnaire ◽  
Small Cell Lung ◽  
European Organization ◽  
Significant Difference

Purpose To investigate whether the effect of hypofractionated thoracic radiotherapy (TRT) is comparable to more standard fractionated radiotherapy (RT) in advanced non–small-cell lung cancer (NSCLC). Patients and Methods A total of 421 patients with locally advanced stage III or stage IV NSCLC tumors were included. Inclusion criteria were inoperable, disease too advanced for curative radiotherapy, and chest symptoms or central tumor threatening the airways. Patients were randomly assigned to three arms: A, 17 Gy per two fractions (n = 146); B, 42 Gy per 15 fractions (n = 145); and C, 50 Gy per 25 fractions (n = 130). Four hundred seven patients were eligible for the study; 395 patients (97%) participated in the health-related quality-of-life (HRQOL) study. The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 and EORTC QLQ-lung cancer–specific module (LC13) were used to investigate airway symptom relief and changes in HRQOL. Assessments were performed before TRT and until week 54. Clinicians' assessments of symptom improvement were at 2, 6, and 14 weeks after completion of TRT. The patients were observed for a minimum of 3 years. Results Baseline prognostic data were equally distributed in the treatment groups. Patient compliance with respect to the HRQOL investigation was minimum 74%. HRQOL and symptom relief were equivalent in the treatment arms. No significant difference in survival among arms A, B, and C was found, with median survival 8.2, 7.0, and 6.8 months, respectively. Conclusion Our data indicate that protracted palliative TRT renders no improvement in symptom relief, HRQOL, or survival when compared with short-term hypofractionated treatment in advanced NSCLC.

The European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life questionnaire cervical cancer module

Cancer ◽  
2006 ◽  
Vol 107 (8) ◽  
pp. 1812-1822 ◽  
Author(s):  
Elfriede R. Greimel ◽  
Karin Kuljanic Vlasic ◽  
Ann-Charlotte Waldenstrom ◽  
Vlatka M. Duric ◽  
Pernille T. Jensen ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cervical Cancer ◽  
Life Questionnaire ◽  
European Organization ◽  
Quality Of Life Questionnaire ◽  
Cancer Module ◽  
Eortc Quality

scholarly journals PSYCHOMETRIC VALIDATION OF THE BAHASA MALAYSIA VERSION OF THE EORTC QLQ-C30 IN MALAYSIAN COLORECTAL CANCER PATIENTS

2020 ◽  
Vol 20 (3) ◽  
pp. 109-116
Author(s):  
Bello Arkilla Magaji ◽  
Foong Ming Moy ◽  
Chee Wei Law ◽  
Ismail Sagap ◽  
April Camilla Roslani
Keyword(s):  
Quality Of Life ◽  
Colorectal Cancer ◽  
Discriminant Validity ◽  
Statistical Significance ◽  
Psychometric Validation ◽  
P Value ◽  
Life Questionnaire ◽  
European Organization ◽  
Significant Difference

This study aimed to assess the validity and reliability of the Bahasa Malaysia (BM) version of European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire core (QLQ-C30) (version 3.0) in Malaysian patients with colorectal cancer. A cross sectional study design was used to obtain data from patients receiving treatment at two teaching hospitals in Kuala Lumpur, Malaysia. Self-administered method was used. Statistical analysis included reliability, convergent and discriminant validity and known-groups comparisons. Statistical significance was based on p value ≤ 0.05. The internal consistency Cronbach’s alpha coefficient (α) was acceptable (> 0.70) in all scales but cognitive (α = 0.56) and pain in patients with stoma bag (α = 0.35). Test-retest coefficients were high (r = 0.93 to 1.00). All items showed adequate convergent validity (r > 0.40) except for questionnaire item 5 “needs help in eating/dressing/washing”. Similarly, criteria for discriminant validity were achieved in all but item 10 “need rest”. Patients with high Karnofsky Performance Scores (KPS) scores reported significantly less dyspnoea (p = 0.021) and appetite loss (p = 0.047) compared to patients with low KPS scores. There was no significant difference between patients with and without stomas. The psychometric properties of the BM version of the QLQ-C30 were comparable to previous studies in other settings. Therefore, the questionnaire could be used to measure quality of life in Malaysian patients with colorectal cancer.

Assessment of Quality of Life and Urinary and Sexual Function After Radical Hysterectomy in Long-Term Cervical Cancer Survivors

2018 ◽  
Vol 28 (4) ◽  
pp. 818-823 ◽  
Author(s):  
Francesco Plotti ◽  
Corrado Terranova ◽  
Stella Capriglione ◽  
Stefania Crispino ◽  
Alessandra Li Pomi ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cervical Cancer ◽  
Sexual Function ◽  
Sexual Activity ◽  
Radical Hysterectomy ◽  
European Organization ◽  
Type Iii

AimsThe aim of this study was to evaluate long-term quality of life and urinary and sexual function in long-term cervical cancer survivors previously treated with radical hysterectomy (RH) type C2/type III.MethodsAll patients who presented at Campus Bio-Medico of Rome for RH type C2/type III for cervical cancer were considered eligible for this retrospective study protocol. We included exclusively patients with complete response to primary treatment with at least 36 months of follow up. Included subjects were interviewed with the European Organization for Research and Treatment of Cancer QLQ-CX24 Questionnaire, European Organization for Research and Treatment of Cancer QLQ-C30, and an Incontinence Impact Questionnaire 7.ResultsFrom January 2004 to June 2014, 251 patients affected by locally advanced cervical cancer were treated at Campus Bio-Medico of Rome treated with type C2/type III RH. At time point of March 2017, 90 patients were included with a mean age of 55.6 ± 8.5 years. The questionnaires were administered after a median follow-up of 49 months after the end of therapy. The symptoms of fatigue, nausea and vomiting, appetite loss, pain, insomnia, and dyspnea, as well as a negative financial impact, were reported as not frequent and rarely disabling. On the contrary, patients frequently reported gastrointestinal complaints. Diarrhea was present in 6% of patients and was referred as mild; constipation was present in 75% of women and was reported as mild in 30% of cases, moderate in 30%, and severe in 15%. Concerning sexual activity, data indicated a good level of sexual enjoyment with a slight worsening of sexual activity. Incontinence was reported in 28% of cases and appeared to be mild and rarely disabling (all mean values <2).ConclusionsWaiting for ongoing randomized controlled trials, this study confirmed that RH may be considered as a useful treatment plan, according to its negligible long-term impact on quality of life, urinary dysfunction, and sexual function.

scholarly journals Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial

2019 ◽  
Vol 149 (7) ◽  
pp. 1133-1139 ◽  
Author(s):  
Lynne M Howells ◽  
Chinenye O O Iwuji ◽  
Glen R B Irving ◽  
Shaun Barber ◽  
Harriet Walter ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Colorectal Cancer ◽  
Adverse Event ◽  
Metastatic Colorectal Cancer ◽  
Gynecologic Oncology Group ◽  
Life Questionnaire ◽  
European Organization ◽  
Significant Difference ◽  
Folfox Chemotherapy

ABSTRACT Background Curcumin is the main active ingredient of the spice turmeric, investigated extensively for putative anticancer properties. Objectives This phase IIa open-labelled randomized controlled trial aimed to assess safety, efficacy, quality of life, neurotoxicity, curcuminoids, and C-X-C-motif chemokine ligand 1 (CXCL1) in patients receiving folinic acid/5-fluorouracil/oxaliplatin chemotherapy (FOLFOX) compared with FOLFOX + 2 g oral curcumin/d (CUFOX). Methods Twenty-eight patients aged >18 y with a histological diagnosis of metastatic colorectal cancer were randomly assigned (1:2) to receive either FOLFOX or CUFOX. Safety was assessed by Common Toxicity Criteria-Adverse Event reporting, and efficacy via progression-free survival (PFS) and overall survival (OS). Quality of life and neurotoxicity were assessed using questionnaires (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 and Functional Assessment of Cancer Treatment-Gynecologic Oncology Group-Neurotoxicity). Plasma curcuminoids were determined with liquid chromatography (LC) electrospray ionization tandem mass spectrometry and CXCL1 by ELISA. Results Addition of daily oral curcumin to FOLFOX chemotherapy was safe and tolerable (primary outcome). Similar adverse event profiles were observed for both arms. In the intention-to-treat population, the HR for PFS was 0.57 (95% CI: 0.24, 1.36; P = 0.2) (median of 171 and 291 d for FOLFOX and CUFOX, respectively) and for OS was 0.34 (95% CI: 0.14, 0.82; P = 0.02) (median of 200 and 502 d for FOLFOX and CUFOX, respectively). There was no significant difference between arms for quality of life (P = 0.248) or neurotoxicity (P = 0.223). Curcumin glucuronide was detectable at concentrations >1.00 pmol/mL in 15 of 18 patients receiving CUFOX. Curcumin did not significantly alter CXCL1 over time (P = 0.712). Conclusion Curcumin is a safe and tolerable adjunct to FOLFOX chemotherapy in patients with metastatic colorectal cancer. This trial was registered at clinicaltrials.gov as NCT01490996 and at www.clinicaltrialsregister.eu as EudraCT 2011-002289-19.

scholarly journals Identificação de Conceitos da Classificação Internacional de Funcionalidade, Incapacidade e Saúde em Medidas de Qualidade de Vida para o Câncer do Colo do Útero

2018 ◽  
Vol 64 (4) ◽  
pp. 509-516
Author(s):  
Luciana Castaneda ◽  
Juliana Cossich Trindade Alves ◽  
Thaissa Hamana de Macedo Dantas ◽  
Diego de Sousa Dantas
Keyword(s):  
Quality Of Life ◽  
Cervical Cancer ◽  
Cancer Therapy ◽  
Functional Assessment ◽  
Life Questionnaire ◽  
European Organization ◽  
Quality Of Life Questionnaire ◽  
Cancer Module

Introdução: o câncer do colo do útero apresenta elevada incidência em países de baixa e média rendas e provoca repercussões negativas sobre a funcionalidade das mulheres. o interesse na mensuração de medidas terapêuticas, que não se restrinjam às medidas do modelo biomédico, vem assumindo destaque no campo da oncologia. a classificação internacional de Funcionalidade (ciF) aparece no cenário mundial como ferramenta de orientação para construção da avaliação biopsicossocial. Objetivo: exemplificar a metodologia para identificação dos componentes da funcionalidade em escalas específicas utilizadas no cuidado oncológico para mulheres com câncer do colo do útero. Método: estudo realizado em três etapas: análise de revisões sistemáticas para identificação dos instrumentos específicos para avaliação de câncer do colo do útero; extração das medidas de avaliação; e ligação dos conceitos contidos nas medidas de desfecho com as categorias correspondentes da ciF por dois revisores independentes. Resultados: na análise do Functional Assessment of Cancer Therapy-Cervix e do European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire Cervical Cancer Module, identificaram-se 72 conteúdos principais ligados a 35 categorias da ciF. destas, 23 referiam-se às funções corporais, oito às atividades e participação, três aos fatores ambientais e uma à estrutura corporal. Conclusão: os dois instrumentos possuem ligação com a ciF, no entanto, exploram de forma insuficiente os fatores contextuais, o que demonstra a necessidade de orientação biopsicossocial nas avaliações em saúde para mulheres com câncer do colo do útero de maneira a contemplar, de forma equânime, os componentes da funcionalidade na aferição dos desfechos terapêuticos.

scholarly journals The Effectiveness of Group-Based Compassion- Focused Therapy on Depression, Anxiety and Improving the Quality of Life in Women With Feminine Cancers

2020 ◽  
pp. 21-27
Author(s):  
Arezou Sourmeh ◽  
Ali Mashhadi ◽  
Zohre Sepehri Shamloo
Keyword(s):  
Quality Of Life ◽  
Analysis Of Covariance ◽  
Life Questionnaire ◽  
Sham Control ◽  
European Organization ◽  
Compassion Focused Therapy ◽  
Significant Difference ◽  
Quasi Experimental ◽  
Eortc Qlq

Introduction: This study aimed to examine the effectiveness of group-based compassion-focused therapy (CFT) on depression, anxiety, and improving the quality of life (QoL) in women with feminine cancers. Methods: A pretest-posttest control‐grouped, quasi‐experimental study was carried out on all women with cancer who were referred to the Omid Hospital of Mashhad in 2019. Thirty patients with various types of feminine cancers were randomly assigned to 12 weeks of group-based compassion-focused therapy (CFT) (n=15) or sham control (n=15). Participants in both conditions completed measures of Beck Depression Inventory-II (BDI-II), Beck Anxiety Inventory (BAI-II), and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) at pretest and posttest. Analysis of covariance was used for data analysis. Results: Our results showed that there was a significant difference between experimental and sham control groups in depression (F= 4/499, P<0.05, d=1.60 large) and anxiety (F=19/99, P<0.01, d=1.96 large), but there was no significant difference in participants’ QoL scale. Conclusions: Group-based CFT could be considered a promising and potentially useful intervention to alleviate the depression and anxiety in cancer patients but it did not affect their QoL. Nevertheless, future randomized trials are needed.

Quality of Life, Urogynecological Morbidity, and Lymphedema After Radical Vaginal Trachelectomy for Early-Stage Cervical Cancer

2015 ◽  
Vol 25 (4) ◽  
pp. 699-706 ◽  
Author(s):  
Ligita Paskeviciute Frøding ◽  
Christian Ottosen ◽  
Berit Jul Mosgaard ◽  
Pernille Tine Jensen
Keyword(s):  
Quality Of Life ◽  
Cervical Cancer ◽  
Matched Control ◽  
Early Stage ◽  
Life Questionnaire ◽  
European Organization ◽  
Bladder Emptying ◽  
Early Stage Cervical Cancer ◽  
Radical Vaginal Trachelectomy

ObjectiveRadical vaginal trachelectomy (RVT) offers a possibility for future childbearing for young women with early-stage cervical cancer. However, the literature on quality of life and self-reported morbidity in patients undergoing RVT is scarce. The aim of this study was to prospectively assess quality of life after RVT with focus on urogynecological morbidity and lymphedema. Furthermore, the aim of this study was to compare results with those in women treated with radical abdominal hysterectomy (RAH) and with age-matched control women from the general population.Methods and MaterialsEighteen patients with early-stage cervical cancer operated with RVT were prospectively included and assessed preoperatively, 3, 6, and 12 months postoperatively using validated questionnaires. Thirty-two patients treated with RAH were included consecutively and assessed once at 12 months postsurgery, whereas an age-matched control group of 30 healthy women was assessed once.ResultsFifty percent of the RVT group and 41% of the RAH reported any grade of incomplete bladder emptying problems at 1 year postsurgery assessment. Eleven percent of the RVT patients and 12.5% of the RAH patients reported severe lymphedema of the legs as assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Cervical Cancer Module. The Global Health Status scores of the RVT patients improved over time but were significantly lower than in the healthy controls during the entire observation time (P= 0.029).ConclusionsPatients treated with RVT for early-stage cervical cancer had persistent bladder emptying problems and lymphedema comparable to those experienced by patients treated with RAH and significantly higher than those reported by healthy control women.

Sign in / Sign up

Export Citation Format

Share Document